FB-401
Atopic Dermatitis
Phase 1/2Completed
Key Facts
About Forte Biosciences
Forte Biosciences' mission is to develop and commercialize novel live biotherapeutic products that modulate the skin microbiome to treat inflammatory and autoimmune conditions. Its primary achievement is advancing its lead candidate, FB-401, through Phase 1/2 clinical trials in atopic dermatitis, generating promising early efficacy and safety data. The company's strategy is to focus its resources on progressing FB-401 through later-stage trials, seeking to establish clinical proof-of-concept for its platform and secure strategic partnerships or eventual regulatory approval. As a micro-cap, single-asset biotech, its near-term trajectory is binary and tied directly to FB-401's clinical outcomes.
View full company profileTherapeutic Areas
Other Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| PEP Biologic™ | Intent Biologics | Unknown |
| HBM7575 (SKB575) | Harbour BioMed | IND Filed |
| ITK inhibitor | Acellera | Pre-clinical |
| Encube-003 | Encube Ethicals | Preclinical |
| ENS-002 (Fermata Derm) | Concerto Biosciences | Pre-clinical |
| Lead Program | MatriSys Bioscience | Phase 1 |
| Atopic Dermatitis Trial | Well Pharma Medical Research | Not Specified |
| MEndoB | Micreos | Pre-clinical |
| Atopic Dermatitis Program | Lxbio Pharmaceuticals | Pre-clinical |
| B244 | AOBiome | Phase 3 |
| CTO1681 | CytoAgents | Pre-clinical |
| DS107 | DS Biopharma | Phase 2 |